CIK 0001850119 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Century Therapeutics, Inc.
Sign in to watch- Ticker
- IPSC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 842040295
- Phone
- 215-981-4000
- Business address
- 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,212
- in 5 filings
Net −$10,212. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 63 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Carr Douglas SVP Finance & Operations | Sale | −266 | $1.52 | $404 | 502,641 |
| 2026-09-14 | Russotti Gregory See Remarks | Sale | −2,587 | $1.93 | $5K | 509,198 |
| 2026-09-14 | Carr Douglas SVP Finance & Operations | Sale | −1,658 | $1.93 | $3K | 502,907 |
| 2026-09-11 | Pfeiffenberger Brent President and CEO | Shares withheld for taxes | −13,850 | $1.94 | $27K | 3,633,839 |
| 2026-09-09 | Truitt Joseph Director | Grant or award · Stock Option (right to buy) | +148,000 | 148,000 | ||
| 2026-09-08 | Russotti Gregory See Remarks | Sale | −534 | $2.05 | $1K | 511,785 |
| 2026-09-08 | Carr Douglas SVP Finance & Operations | Sale | −254 | $2.05 | $521 | 504,565 |
| 2026-09-04 | Pfeiffenberger Brent President and CEO | Shares withheld for taxes | −463 | $2.11 | $977 | 3,633,839 |
| 2026-08-14 | Pfeiffenberger Brent President and CEO | Shares withheld for taxes | −31,172 | $1.92 | $60K | 3,634,302 |
| 2026-08-03 | Carr Douglas SVP Finance & Operations | Sale | −275 | $1.98 | $544 | 504,819 |
| 2026-06-12 | Russotti Gregory See Remarks | Sale | −2,584 | $2.23 | $6K | 512,319 |
| 2026-06-12 | Carr Douglas SVP Finance & Operations | Sale | −1,654 | $2.23 | $4K | 505,094 |
| 2026-06-11 | Cowan Chad Chief Scientific Officer | Shares withheld for taxes | −358 | $2.24 | $802 | 1,175,322 |
| 2026-06-11 | Pfeiffenberger Brent President and CEO | Shares withheld for taxes | −13,849 | $2.24 | $31K | 3,665,474 |
| 2026-06-11 | Murphy Martin Patrick Director | Grant or award · Stock Option (right to buy) | +74,000 | 74,000 | ||
| 2026-06-11 | Lee Han Myung Director | Grant or award · Stock Option (right to buy) | +74,000 | 74,000 | ||
| 2026-06-11 | Riva Alessandro Director | Grant or award · Stock Option (right to buy) | +74,000 | 74,000 | ||
| 2026-06-11 | Blackwell Kimberly Director | Grant or award · Stock Option (right to buy) | +74,000 | 74,000 | ||
| 2026-06-11 | Quimi Daphne Director | Grant or award · Stock Option (right to buy) | +74,000 | 74,000 | ||
| 2026-06-08 | Russotti Gregory See Remarks | Sale | −524 | $2.11 | $1K | 514,903 |
Page 1 of 6 · 118 trades